QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 780 participants.

Also called NCT07441317

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 780 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07441317
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07441317. Randomized; quadruple masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Condition
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Intervention (Drug)
QLC7401
Intervention (Drug)
Placebo
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07441317
Content hash
de9957db52b4cd9dacfaaa24e414f89a525823c7f57752e6aa256e3b3a595df9